BIOMAT Database Logo BIOMAT Database Logo

Secondary prevention of meningococcal disease. No evidence exists to support use of penicillin. 1996

T Stokes, and R Shukla, and P Monk

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T Stokes, and R Shukla, and P Monk
Secondary prevention of meningococcal disease. Penicillin is not recommended in British guidelines.
June 1996, BMJ (Clinical research ed.),
T Stokes, and R Shukla, and P Monk
Secondary prevention of meningococcal disease.
March 1996, BMJ (Clinical research ed.),
T Stokes, and R Shukla, and P Monk
[Prevention of secondary cases of meningococcal disease].
April 1983, Ugeskrift for laeger,
T Stokes, and R Shukla, and P Monk
Prevention of secondary cases of meningococcal disease in Denmark.
June 2000, Epidemiology and infection,
T Stokes, and R Shukla, and P Monk
Secondary prevention of meningococcal disease. Cases are "unavoidably unpredictable".
June 1996, BMJ (Clinical research ed.),
T Stokes, and R Shukla, and P Monk
Ecstasy and neurodegeneration. No evidence of neurotoxicity exists.
August 1996, BMJ (Clinical research ed.),
T Stokes, and R Shukla, and P Monk
No evidence exists that "anti-dementia" drugs modify disease or improve outcome.
April 2014, BMJ (Clinical research ed.),
T Stokes, and R Shukla, and P Monk
Short-course penicillin therapy for meningococcal disease: accumulating evidence and persistent uncertainty.
September 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
T Stokes, and R Shukla, and P Monk
Secondary prevention of meningococcal disease. British guidelines should have been considered.
June 1996, BMJ (Clinical research ed.),
T Stokes, and R Shukla, and P Monk
Early parenteral penicillin in meningococcal disease.
August 1992, BMJ (Clinical research ed.),
Copied contents to your clipboard!